David S. Boss

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers

Peter C.C. Fong, David S. Boss, Timothy A. Yap et al. · New England Journal of Medicine · 2009 · 3.6K citations · Full text

Medicine, Oncology, Pharmacology +17

Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in <i>BRCA</i> Carrier Ovarian Cancer Correlating With Platinum-Free Interval

Peter C.C. Fong, Timothy A. Yap, David S. Boss et al. · Journal of Clinical Oncology · 2010 · 992 citations · Full text

Medicine, Oncology, Pharmacology +17

A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours

David S. Boss, Hilary Glen, Jos H. Beijnen et al. · British Journal of Cancer · 2012 · 185 citations · Full text

Medicine, Oncology, Pharmacology +14

Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors

Pasi A. Jänne, David S. Boss, D. Ross Camidge et al. · Clinical Cancer Research · 2011 · 182 citations · Full text

Medicine, Oncology, Pharmacology +17

Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors

David S. Boss, Petronella O. Witteveen, J. van der Sar et al. · Annals of Oncology · 2010 · 109 citations · Full text

Medicine, Oncology, Pharmacology +17